Onco Targets Ther. 2016 Jul 21;9:4441-51. doi: 10.2147/OTT.S105239. eCollection 2016.

Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results.

Pham PV¹, Le HT¹, Vu BT¹, Pham VQ¹, Le PM¹, Phan NL¹, Trinh NV¹, Nguyen HT¹, Nguyen ST¹, Nguyen TL², Phan NK¹.

Abstract

BACKGROUND:

Breast cancer (BC) is one of the leading cancers in women. Recent progress has enabled BC to be cured with high efficiency. However, late detection or metastatic disease often renders the disease untreatable. Additionally, relapse is the main cause of death in BC patients. Breast cancer stem cells (BCSCs) are considered to cause the development of BC and are thought to be responsible for metastasis and relapse. This study aimed to target BCSCs using dendritic cells (DCs) to treat tumor-bearing humanized mice models.

MATERIALS AND METHODS:

NOD/SCID mice were used to produce the humanized mice by transplantation of human hematopoietic stem cells. Human BCSCs were injected into the mammary fat pad to produce BC humanized mice. Both hematopoietic stem cells and DCs were isolated from the human umbilical cord blood, and immature DCs were produced from cultured mononuclear cells. DCs were matured by BCSC-derived antigen incubation for 48 hours. Mature DCs were vaccinated to BC humanized mice with a dose of 10(6) cells/mice, and the survival percentage was monitored in both treated and untreated groups.

RESULTS:

The results showed that DC vaccination could target BCSCs and reduce the tumor size and prolong survival.

CONCLUSION:

These results suggested that targeting BCSCs with DCs is a promising therapy for BC.